BL-M07D1 Clinical Trials
14 recruitingDrug
Phase 27Phase 16Phase 35
Showing 1–14 of 14 trials
Recruiting
Phase 1Phase 2
A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors
Her2-positive/Low-expression Urinary and Digestive Tract Tumors
Sichuan Baili Pharmaceutical Co., Ltd.42 enrolled1 locationNCT06031584
Recruiting
Phase 1
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Breast CancerEsophageal CancerGastric Cancer+7 more
SystImmune Inc.280 enrolled17 locationsNCT06293898
Recruiting
Phase 2
A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC
Non-squamous Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.80 enrolled1 locationNCT07264816
Recruiting
Phase 3
A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy
HER2-positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.1,450 enrolled2 locationsNCT06830889
Recruiting
Phase 3
A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer
HER2-low Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.566 enrolled2 locationsNCT06957886
Recruiting
Phase 3
A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC
Non-squamous Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.440 enrolled1 locationNCT07178795
Recruiting
Phase 3
A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-positive Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction Adenocarcinoma
Gastroesophageal Junction AdenocarcinomaGastric Adenocarcinoma
Sichuan Baili Pharmaceutical Co., Ltd.490 enrolled2 locationsNCT07152405
Recruiting
Phase 2Phase 3
A Study of BL-M07D1 With or Without Pertuzumab Versus Taxane + Trastuzumab and Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
HER2-positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.120 enrolled30 locationsNCT06891833
Recruiting
Phase 1Phase 2
A Study of BL-M07D1 in Patients With HER2-expressing Recurrent or Metastatic Gynecologic Malignancies
Gynecological Malignancies
Sichuan Baili Pharmaceutical Co., Ltd.138 enrolled1 locationNCT06131450
Recruiting
Phase 1
Phase I Clinical Study of BL-M07D1 in Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid Tumors
Other Solid TumorsLocally Advanced or Metastatic Digestive Tract Tumors
Sichuan Baili Pharmaceutical Co., Ltd.26 enrolled1 locationNCT05631964
Recruiting
Phase 1
A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Low Expression Breast Cancer and Other Solid Tumors
Breast CancerLocally Advanced or Metastatic Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.26 enrolled7 locationsNCT05461768
Recruiting
Phase 2
A Study of BL-M07D1 Combination Therapy in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma
HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma
Sichuan Baili Pharmaceutical Co., Ltd.40 enrolled1 locationNCT06423885
Recruiting
Phase 1Phase 2
A Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung Cancer
Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.98 enrolled1 locationNCT06114511
Recruiting
Phase 2
A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer
HER2-positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.120 enrolled1 locationNCT06445400